|
Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod
March 20, 2017
LAVAL, Quebec and SOPHIA ANTIPOLIS, France, March 20, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. (Euronext Paris: FR0013018124, COX) today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA date of August 24, 2017 for its decision on the New Drug Application (NDA) for latanoprostene bunod ophthalmic solution, 0.024%. Latanoprostene bunod is an intraocular pressure (IOP) lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma (OAG) or ocular hypertension (OHT).
If approved, latanoprostene bunod would be the first nitric-oxide donating prostaglandin F2α analog for ophthalmic use.
"This is an exciting development in our journey to bring this new treatment option to the more than 3 million1 patients in the U.S. with open angle glaucoma and ocular hypertension, and address a significant unmet medical need," said Joseph C. Papa, Chairman and CEO of Valeant. "Valeant is committed to delivering therapies that make a difference in patients' lives, and our work on latanoprostene bunod is a strong example of that."[...]
ir.valeant.com/news-releases/2017/03-20-2017-210050230
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
89 | Bausch Health - ehemals Valeant - u.a. Pharmawerte | macumba | newson | 29.07.22 10:39 | ||
7 | Valeant mag steigen | GaborPiscis | GaborPiscis | 25.04.21 02:04 | ||
11 | 2.136 | Verdopplung | nemo140262 | DrZaubrlhrling | 24.04.21 23:04 | |
2 | 147 | Welcher dieser 2 Werte macht am schnellsten | martin30sm | bozkurt7 | 03.05.17 11:06 |